These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32520788)

  • 41. Metabolism and pharmacokinetics of radium-223 in prostate cancer.
    Yeku O; Slovin SF
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):843-9. PubMed ID: 25740232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safe Use of Radium-223 Dichloride (
    Aro JL; Dinning SI; Leung EY; Zuckier LS
    J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S36-S40. PubMed ID: 31383575
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
    Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
    Pandit-Taskar N; Larson SM; Carrasquillo JA
    J Nucl Med; 2014 Feb; 55(2):268-74. PubMed ID: 24343987
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SNMMI Procedure Standard/EANM Practice Guideline for Brain [
    Arbizu J; Morbelli S; Minoshima S; Barthel H; Kuo P; Van Weehaeghe D; Horner N; Colletti PM; Guedj E
    J Nucl Med; 2024 Oct; ():. PubMed ID: 39419552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapy of bone metastases with radium-223. German guidelines].
    Pöppel TD; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Scheidhauer K; Schenck M; Sonnenschein W; Gabriel M
    Nuklearmedizin; 2016 Sep; 55(5):177-86. PubMed ID: 27417067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Critical Care Network in the State of Qatar.
    Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
    Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
    Jadvar H; Challa S; Quinn DI; Conti PS
    Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.
    Coleman R; Brown J; Rathbone E; Flanagan L; Reid A; Kendall J; Howell S; Twelves C; Palmieri C; Anand A; MacPherson I; Brown S
    Trials; 2020 Jan; 21(1):89. PubMed ID: 31941523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy.
    Erickson BA; Demanes DJ; Ibbott GS; Hayes JK; Hsu IC; Morris DE; Rabinovitch RA; Tward JD; Rosenthal SA
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):641-9. PubMed ID: 21106308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for Intensity-modulated Radiation Therapy (IMRT).
    Hartford AC; Galvin JM; Beyer DC; Eichler TJ; Ibbott GS; Kavanagh B; Schultz CJ; Rosenthal SA; ;
    Am J Clin Oncol; 2012 Dec; 35(6):612-7. PubMed ID: 23165357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma.
    American College of Radiology
    J Am Coll Surg; 2007 Aug; 205(2):362-376. PubMed ID: 17660085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate cancer - Therapy with radium-223.
    Brito AE; Amorim BJ; Martello M; Bernardo WM; Etchebehere E;
    Rev Assoc Med Bras (1992); 2017 Dec; 63(12):1019-1023. PubMed ID: 29489974
    [No Abstract]   [Full Text] [Related]  

  • 56. Radium-223 Therapy of Bone Metastases in Prostate Cancer.
    Nilsson S
    Semin Nucl Med; 2016 Nov; 46(6):544-556. PubMed ID: 27825434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Targeted radionuclide therapy for castration-resistant prostate cancer].
    Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
    Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radium-223 dichloride therapy in breast cancer with osseous metastases.
    Takalkar A; Paryani B; Adams S; Subbiah V
    BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26581701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
    ; Parker C; Lewington V; Shore N; Kratochwil C; Levy M; Lindén O; Noordzij W; Park J; Saad F
    JAMA Oncol; 2018 Dec; 4(12):1765-1772. PubMed ID: 30326033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.